Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response
Autore:
Borawski, J; Naumnik, B; Pawlak, K; Mysliwiec, M;
Indirizzi:
Med Acad Bialystok, Dept Nephrol & Internal Med, PL-15540 Bialystok, Poland Med Acad Bialystok Bialystok Poland PL-15540 PL-15540 Bialystok, Poland
Titolo Testata:
NEPHROLOGY DIALYSIS TRANSPLANTATION
fascicolo: 7, volume: 16, anno: 2001,
pagine: 1442 - 1447
SICI:
0931-0509(200107)16:7<1442:EDMVWF>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC-RENAL-FAILURE; C-REACTIVE PROTEIN; CHRONIC-HEMODIALYSIS PATIENTS; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; HEMOSTATIC FACTORS; ANGINA-PECTORIS; CHRONIC UREMIA; SUDDEN-DEATH;
Keywords:
acute phase response; blood pressure; cardiovascular disease; endothelium; haemodialysis; von Willebrand factor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Borawski, J Med Acad Bialystok, Dept Nephrol & Internal Med, 14 Zurawia St, PL-15540 Bialystok, Poland Med Acad Bialystok 14 Zurawia St Bialystok Poland PL-15540 nd
Citazione:
J. Borawski et al., "Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response", NEPH DIAL T, 16(7), 2001, pp. 1442-1447

Abstract

Background, Increased plasma soluble von Willebrand factor antigen (VWF:Ag) level, a marker of vascular endothelial cell dysfunction, is a strong predictor of atherosclerotic cardiovascular disease (CVD) in the general population. We studied cross-sectional associations between vWF:Ag level, prevalence of CVD, and related factors including pre-dialysis arterial blood pressure (BP) and some markers of inflammation in maintenance haemodialysis (HD) patients. Methods and results. Plasma vWF:Ag level measured by an enzyme-linked immunosorbent assay (ELISA) was higher in 110 HD patients than in 20 controls. On bivariate regression analysis, vWF:Ag level was directly associated withthe presence of CVD, age, fibrinogen and the use of enoxaparin (vs unfractionated heparin) during HD procedures, and inversely with albumin and pre-dialysis BP. The patients with prevalent CVD were older, had higher vWF:Ag, white blood cell and platelet counts, fibrinogen and triglycerides, lower albumin levels, and were less frequently on combination antihypertensive therapy. Multivariable analyses identified low pre-dialysis BP. hypoalbuminaemia and hyperfibrinogenaemia (in descending order of significance) as independent predictors of high vWF:Ag level. There were no associations between VWF : Ag levels and gender. ABO blood type, smoking, body mass index. renal failure cause, duration of HD therapy, K-t/V, normalized protein catabolic rate, dialysate buffers, dialysers, viral hepatitis, erythropoietin treatment, specific antihypertensive drugs, haemoglobin, white blood cell and platelet counts, liver enzymes. phosphorous, total cholesterol, and triglycerides. Conclusion. Elevated plasma levels of endothelial dysfunction marker vWF:Ag in maintenance HD patients are associated with established cardiovascularmortality risk factors such as low pre-dialysis blood pressure and the activated acute phase response.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 22:24:46